An Open-Label Evaluation of the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment
This is an open-label study evaluating the safety and tolerability of SAGE-718 and its effects on cognitive, neuropsychiatric, and motor symptoms in participants with PD-MCI. Eligible participants with a confirmed diagnosis of idiopathic PD by 2015 Movement Disorder Society (MDS) criteria at Screening and who meet MDS Task Force Criteria for MCI in PD (excluding requirement for UK PD Brain Bank diagnostic criteria) will receive a 3.0 mg dose of SAGE-718 daily for 14 days.
Ages 50- 90
MMSE Score of 22-30
A Phase III, Multinational, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, Safety and Tolerability Study of BAN2401 in Patients with Early Alzheimer’s Disease. Subjects will undergo brain MRI, amyloid and tau PET Scans, cognitive testing, physical and neurological examination. Study participation consists of an 18-month study in which infusions are given biweekly. Participants will be from two clinical subgroups: Mild Cognitive Impairment (MCI) due to Alzheimer's Disease or Mild Alzheimer's Disease (Mild AD) dementia. Participants that complete the study treatment will be eligible to participate in the Extension Phase.
MMSE Score 12-22
A Phase II, Randomized, Double-blind, Placebo-Controlled, Efficacy, Safety and Tolerability study of COR388 HCI (GAIN) in patients with probable Alzheimer’s disease. Subjects will receive brain MRI or CT scan, cognitive testing, neurological examination and dental examination. Study participation consists of a 12-month trial in which dosing occurs twice daily (a.m. and p.m.) in pill form.
CNS Patients with LP orders. SeraTrials11007
A prospective collection of additional cerebral spinal fluid (CSF) for research from patients currently scheduled to undergo a lumbar puncture procedure due to a CNS disease. An additional 15ml CSF will be collected in addition to blood and urine specimen collection. Samples obtained from this study will be used in the development and improvement of diagnostic test kits and devices, biomarker discovery, as control specimens, as well as general disease states, and clinical/medical research. Participants will be required to attend a single study visit where they will undergo a neurological examination to confirm trial eligibility, undergo the lumbar puncture procedure, specimen collections, and post-procedure observation.
CNS Patients or Healthy Volunteers without LP orders. SeraTrials11008
A prospective collection of cerebral spinal fluid (CSF), blood and urine samples from patients diagnosed with or suspected to have neurological disorders or infections of CSF and healthy volunteers for research. The purpose of this study is to obtain 20ml cerebral spinal fluid (CSF), blood, and one cup urine from patients diagnosed with neurological disorders and healthy volunteers to be used in the development and improvement of diagnostic test kits and devices, biomarker discovery, as control specimens, as well as general disease state, clinical/medical research. Participants will be required to attend a single study visit where they will undergo a neurological examination to confirm trial eligibility, undergo the lumbar puncture procedure, specimen collections, and post-procedure observation.
14271 Metropolis Avenue, Suite A
Fort Myers, FL 33912 • 239-939-7777
Neuropsychiatric Research Center